Toward better outcomes in Sjögren's syndrome: The promise of a stratified medicine approach

Ghaith Noaiseh, Alan N. Baer

Research output: Contribution to journalReview article

Abstract

Sjögren's syndrome is a systemic autoimmune disease defined by its targeted inflammation of the salivary and lacrimal glands, resulting in dry mouth and eyes in the majority and persistent or recurrent salivary gland enlargement in a minority of those affected. Involvement of major organs, an increased risk of lymphoma, and autoantibodies against ubiquitous cellular ribonucleoproteins define some of its systemic features. Those affected have a high symptom burden and the development of disease-modifying therapies is thus an urgent need. A stratified medicine approach offers promise as a means of targeting specific therapies to patients for whom the mechanism of action is most relevant. Implementation of this approach will require an understanding of the pathophysiological processes underlying different patient subsets, and then identifying or developing a drug that targets this pathway. Such therapies would be most effective if implemented early in the disease course before the advent of adverse outcomes or glandular damage. This review will provide a disease overview followed by an analysis of the feasibility of a stratified medicine approach, focusing on the disease heterogeneity, predictors of disease progression and adverse outcomes, and recent advances in the development of relevant outcome measures and new therapies.

Original languageEnglish (US)
Article number101475
JournalBest Practice and Research: Clinical Rheumatology
DOIs
StateAccepted/In press - Jan 1 2020

    Fingerprint

Keywords

  • Biomarkers
  • Disease-modifying therapy
  • Personalized medicine
  • Sjögren's syndrome
  • Stratified medicine

ASJC Scopus subject areas

  • Rheumatology

Cite this